Form 4: First Wave BioPharma CFO Sells Shares to Cover Tax Obligations

Sarah Romano, CFO of First Wave BioPharma, sold 75 shares of common stock on April 1, 2024, to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).

Summary

• On April 1, 2024, Sarah Romano, the Chief Financial Officer of First Wave BioPharma, Inc. (FWBI), sold 75 shares of the company's common stock.
• The sale was executed at a price of $4.2294 per share.
• This transaction was conducted to cover tax withholding obligations associated with the vesting and settlement of Restricted Stock Units (RSUs).
• The sale was mandated by the issuer's election to require the satisfaction of tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary transaction by the Reporting Person.
• Following the transaction, Romano still beneficially owns 19,111 shares, which includes unvested RSUs.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing a stock sale for tax purposes. It doesn't inherently convey positive or negative sentiment.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like the CFO, trade their company's stock. These filings provide transparency into insider transactions.

Stakeholder Impact

• The sale of a small number of shares by the CFO is unlikely to have a significant impact on shareholders.

Key Dates

Keywords

Form 4, FWBI, First Wave BioPharma, Sarah Romano, CFO, stock sale, tax withholding, RSU, Restricted Stock Units